There are no immediate consequences of the PRAC’s review as daclizumab is no longer authorised in the EU following 12 reports (3 fatal) of serious inflammatory brain disorders worldwide, including encephalitis and meningoencephalitis.
A full assessment report on the review will be published shortly.